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Abstract
Background: Though the vast majority of seminal trials for locally advanced esophageal cancer (EC) utilized three-
dimensional conformal radiotherapy (3DCRT), the advanced and highly conformal technology known as intensity-
modulated radiotherapy (IMRT) can decrease doses to critical cardiopulmonary organs. To date, there have been no
studies comparing both modalities as part of definitive chemoradiation (dCRT) for EC. Herein, we investigated local
control and survival and evaluated clinical factors associated with these endpoints between cohorts.
Methods: We retrospectively analyzed 93 patients (3DCRT n = 49, IMRT n = 44) who received dCRT at our institution
between 2000 and 2012 with the histologic diagnosis of nonmetastatic EC, a Karnofsky performance status of ≥70,
curative treatment intent, and receipt of concomitant CRT. Patients were excluded if receiving <50 Gy. Kaplan-Meier
analysis was used to evaluate the endpoints of local relapse rate (LR), progression-free survival (PFS), and overall survival
(OS). Cox proportional hazards modeling addressed factors associated with outcomes with univariate and multivariate
approaches. Rates of acute toxicities and basic dosimetric parameters were compared between 3DCRT and IMRT
patients.
Results: Mean follow-up was 34.7 months. The 3-year LR was 28.6% in the 3DCRT group and 22.7% in the IMRT group
(p = 0.620). Median PFS were 13.8 and 16.6 months, respectively (p = 0.448). Median OS were 18.4 and 42.0 months,
respectively (p = 0.198). On univariate analysis, only cumulative radiation dose was associated with superior LR (hazard
ratio (HR) 0.736; 95% confidence interval (CI) 0.635 – 0.916, p = 0.004). Factors clearly affecting survival were not
observed.
Conclusions: When comparing 3DCRT- versus IMRT-based dCRT, no survival benefits were observed. However, we
found a lower local recurrence rate in the IMRT group potentially owing to dose-escalation. Prospective data are
needed to verify the presented results herein.
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Background
Though the current standard of care for locally advanced
esophageal cancer (EC) is neoadjuvant chemoradiotherapy
(nCRT) followed by resection [1, 2], the latter is also asso-
ciated with surgical morbidity and mortality. Two ran-
domized trials have addressed nCRT versus definitive CRT
(dCRT); despite local control (LC) benefits with surgery,
no differences were discerned in distant metastasis or
survival [3, 4]. Thus, dCRT is performed – and is indeed a
viable recommendation – for select ECs [1, 5, 6].
However, virtually all seminal clinical trials for both
nCRT and dCRT have utilized three-dimensional con-
formal radiotherapy (3DCRT) [2–4, 7, 8]. The advanced
and highly conformal technology of intensity-modulated
radiotherapy (IMRT) has heretofore been studied only in
limited capacities [9–13]. It remains an attractive modal-
ity largely owing to the intimate anatomic relationship of
the esophagus with both lungs and the heart. Indeed,
several publications have posited a positive correlation
between radiation dose to the lungs [14–18] and heart
[19–22], with the risk of toxicities in these structures.
Hence, the high conformality of IMRT could theoretic-
ally afford fewer toxicities to these organs-at-risk
(OARs), especially in the setting of relative dose-
escalation with dCRT, but supportive data are currently
lacking. The aim of this study was to compare outcomes
and acute toxicity of EC patients receiving definitive
dCRT with either 3DCRT or IMRT.
Methods
This single-institutional study was approved by the
university institutional review board and ethics commit-
tee, and patient/treatment/outcomes were retrospect-
ively collected from an institutional database. Herein, we
evaluated 93 patients (2000–2012) treated definitively
for locally advanced EC. Specifically, inclusion criteria
were histologically-proven esophageal squamous cell or
adenocarcinoma, Karnofsky performance status (KPS)
≥70, curative treatment intent, systemic workup negative
for distant metastases, and receipt of concomitant CRT.
Patients were excluded if receiving <50 Gy definitively,
as per prior studies [2]. The choice of radiation modality
(IMRT or 3DCRT) was made at the radiation oncologist’s
discretion, predominantly influenced by institutional
guidelines and availability at the time of treatment
planning.
All patients underwent systemic workup with referring
providers prior to commencing CRT and a CT for
radiation treatment planning. The gross tumor was first
contoured, followed by a 4–5 cm craniocaudal margin
(0.5-1 cm radially) and inclusion of locoregional lymph-
atic pathways to form the clinical target volume (CTV);
another isotropic margin 0.5-1 cm was added to con-
struct the planning target volume (PTV). If a boost was
applied, the boost CTV was defined by adding a margin
of 1.5-2 cm craniocaudally and 0.5-1 cm radially. The
boost CTV-to-PTV margin was 0.5-1 cm in any direc-
tion. 3DCRT utilized a 3-5-field beam arrangement.
IMRT was planned using either a step-and-shoot design
or helical application mode. Boosts were either sequen-
tial or simultaneous. Image guidance was utilized in
more contemporary time periods.
Chemotherapy was administered concomitantly with RT
in all patients, and consisted of cisplatin 20 mg/m2 + 5-FU
1000 mg/m2 over 5 days at weeks 1, 5, 9, and 13. While
receiving CRT, patients were monitored weekly on
treatment with toxicity assessments, and at regular follow-
up intervals with imaging.
Statistical analyses were performed using R (version
3.0.2, R Development Core Team, 2013, URL: http://
www.r-project.org/) combined with the packages ‘splines’,
‘survival’ (version 2.37-7, Therneau, 2014) and ‘xtable’
(version 1.7-1, Dahl, 2013). Tests were two-sided with
p < 0.05 considered significant. Since this was an ex-
ploratory trial, all p-values are interpreted descriptively
and no adjustment for multiple testing is applied. Chi-s-
quared test assessed measures of association in fre-
quency tables, and the t-test evaluated the equality of
population distributions. Survival analysis was done
using Kaplan-Meier methodology. A local relapse (LR)
was defined as the locally recurrent disease including a
biopsy-proven or radiologically-suspicious lesion in close
proximity to the initial disease. Progression-free survival
(PFS) was defined as the time from last oncologic treat-
ment to death, local recurrence or distant metastasis,
whichever occurred first. Overall survival (OS) referred
to the time interval between initial diagnosis to death
from any cause, with censorship based on particular
follow-up times. The Cox proportional hazards model
was used for univariate analysis (UVA) and multivariate
analysis (MVA) to assess the effect of several clinical
factors on LR, PFS and OS. The Wald test was used to
assess the predictive value of the covariates in the
model.
Toxicities were assigned at the time of initial occur-
rence by the treating physician according to the Com-
mon Terminology Criteria for Adverse Events v4.0, and
retrospectively reviewed for purposes of this study.
Results
Median and mean follow-up for all patients was
20.1 months and 34.7 months, respectively (range, 3 –
150.1 months). Table 1 displays clinical characteristics of
the patient population. Of note, differences between
groups included a more proximally localized upper
tumor border (23.7 vs. 26.4 cm from the dental arcade,
p = 0.031) and a higher mean cumulative radiation dose
(57.2 vs. 55.4 Gy, p = 0.01) for the IMRT group.
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Figure 1 illustrates results of local relapse rate (LR),
OS and PFS for both groups. The 1- and 3-year LR was
20.4% and 28.6% in the 3DCRT group and 15.9% and
Table 1 Characteristics of the patient cohort separated by
radiotherapy technique
Characteristic 3DCRT IMRT p-value
(n = 49) (n = 44)
Age – years 0.448
Mean 64.2 62.9
Median 65 62
Range 45-84 40-79
Male Sex – no. (%) 42 (85.7) 36 (81.8%) 0.610
KPS – % 0.516
Mean 85.5 86.6
Median 90 90
Range 70-100 70-100
T-Stage – no. (%) 0.331
T1 0 (0) 0 (0)
T2 13 (26.5) 8 (18.2)
T3 26 (53.1) 30 (68.2)
T4 10 (20.4) 6 (13.2)
N-Stage – no. (%) 0.507
N0 10 (20.4) 11 (25)
N1 28 (57.1) 26 (59.1)
N2 11 (22.4) 6 (13.6)
N3 0 (0) 1 (2.3)
Grade – no. (%) 0.367
G1 1 (2) 2 (4.5)
G2 20 (40.8) 23 (52.3)
G3 28 (57.1) 19 (43.2)
Pretreatment Hemoglobin – g/dl 0.394
Mean 12.8 13.1
Median 12.6 13.5
Range 9.5-15.9 5.2-17.1
Location (Distance from dental
arcade to cranial tumor
border) – cm
0.031
Mean 26.4 23.7
Median 27 22
Range 15-37 10-38
Histology – no. (%) 0.491
Squamous cell 41 (83.7) 39 (88.6)
Adeno 8 (16.3) 5 (11.4)
Cumulative RT dose – Gy 0.010
Mean 55.4 57.2
Median 54 56.8
Range 50.4-70.2 50–61.2
Fig. 1 Kaplan-Meier estimates of a OS, b PFS and c LR for both groups
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22.7% in the IMRT group, respectively (p = 0.620). Me-
dian PFS in the respective groups were 13.8 and
16.6 months, which corresponded to 3- and 5-year PFS
of 32.4% and 21% compared to 37.4% and 31.6%,
respectively (p = 0.448). Median OS in the respective
cohorts were 18.4 and 42.0 months, which corresponded
to 3- and 5-year OS of 35.5% and 23.9% compared to
50.9% and 38.9%, respectively (p = 0.198).
Univariate analysis (UVA) determined factors associ-
ated with LR, PFS, and OS (Table 2). None of the inves-
tigated factors influenced OS or PFS with statistically
significant impact. However, there was a trend for worse
OS and PFS for high-grade disease (p = 0.052 and
p = 0.089, respectively) and for improved PFS with
higher pre-treatment hemoglobin levels (p = 0.057).
Higher cumulative RT doses beneficially impacted LR on
UVA (p = 0.004). Multivariate analysis (MVA) included
the factors RT technique, KPS, T-stage, N-stage,
Grading, tumor histopathology and RT dose. Besides the
confirmation of a beneficial impact of increased RT
doses on LR (HR 0.686, 95%-CI 0.524 – 0.897;
p = 0.006) and a borderline significant worse OS for
high-grade tumors (HR 1.743, 95%-CI 1.003 – 3.029;
p = 0.049) MVA did not reveal any further significant
findings.
Acute, radiation-related toxicities experienced by both
cohorts are displayed in Table 3. These predominantly
included dysphagia, radiodermatitis and nausea/vomit-
ing. Of note, dysphagia was observed in 70.5% for
patients in the IMRT group vs. 42.9% in the 3DCRT
group (p = 0.067). Owing to a short follow-up period
and assumed issues with data integrity regarding late
toxicity reporting in the cohorts, late toxicities were
unable to be reliably presented herein.
In terms of dosimetric analysis, detailed treatment
plan information was available in 76 patients. Basic
dosimetric parameters of 3DCRT and IMRT plans are
shown in Table 4. A trend towards larger PTVs was ob-
served for IMRT (p = 0.060). There were no significant
differences in normal tissue exposure between treatment
techniques.
Discussion
In our study cohort, the choice of radiation technique
(3DCRT or IMRT) did not significantly influence sur-
vival in definitive chemoradiotherapy for esophageal
cancer patients. These results correspond to previous
findings [9, 10], yet contradictory results have been
presented as well [13]. Nevertheless, the value of such
an analysis is not diminished, because there is still a lack
of data regarding the potential value of IMRT in the
definitive, relatively dose-escalated setting. This will un-
doubtedly be an important issue in the coming years as
the use of IMRT for EC increases [23].
The novelty and emphasis of our data were aimed at
detecting differences in outcome endpoints in the setting
of relative dose-escalation (in the definitive setting).
Although median OS was 42.0 months with IMRT com-
pared to 18.4 months with 3DCRT, this difference did
not reach statistical significance. However, LR was sig-
nificantly increased by higher cumulative radiation
doses. Interestingly, radiation modality did not show a
noticeable impact on LR though confounder analysis
revealed a significantly higher mean cumulative RT dose
in the IMRT group. We suppose that this difference be-
tween both groups, namely 1.8 Gy (3DCRT 55.4 Gy vs.
IMRT 57.2 Gy, p = 0.01), is too small to translate into a
considerable outcome difference of radiation techniques.
However, our data reveal a dose-relationship resulting in
an increased local tumor control with higher radiation
doses. This finding is in line with other investigations
that have noted outcome enhancements for dose-
Table 2 Hazard ratios (HR) with 95%-confidence intervals (CI) in univariate analysis for OS, PFS and LR
OS PFS LR
Parameter HR [95% CI] p-value HR [95% CI] p-value HR [95% CI] p-value
RT mode (IMRT vs. 3DCRT) 0.716 [0.430; 1.191] 0.198 0.830 [0.512; 1.344] 0.448 0.812 [0.356; 1.852] 0.620
Age (continuous) 1.006 [0.978; 1.035] 0.676 1.009 [0.981; 1.037] 0.525 0.962 [0.906; 1.022] 0.211
KPS (continuous) 1.004 [0.973; 1.035] 0.816 1.024 [0.992; 1.057] 0.138 0.988 [0.940; 1.039] 0.644
T-stage (T3/4 vs. T1/2) 1.177 [0.637; 2.178] 0.603 1.226 [0.679; 2.212] 0.499 1.170 [0.411; 3.328] 0.768
N-stage (N1-3 vs. N0) 1.493 [0.779; 2.863] 0.228 1.399 [0.764; 2.561] 0.277 1.218 [0.408; 3.635] 0.723
Grade (G3 vs. G1/2) 1.651 [0.996; 2.737] 0.052 1.518 [0.938; 2.456] 0.089 1.040 [0.455; 2.374] 0.926
Pretreatment Hemoglobin 0.930 [0.821; 1.054] 0.255 0.886 [0.783; 1.003] 0.057 0.975 [0.821; 1.157] 0.768
Location 1.002 [0.960; 1.046] 0.935 0.992 [0.952; 1.033] 0.689 1.030 [0.958; 1.107] 0.422
Histology (Adeno vs. SCC) 1.555 [0.786; 3.076] 0.205 1.630 [0.851; 3.125] 0.141 1.354 [0.489; 3.750] 0.560
RT dose (continuous) 0.946 [0.881; 1.015] 0.122 0.955 [0.893; 1.021] 0.173 0.763 [0.635; 0.916] 0.004
Treatment year (continuous) 1.021 [0.934; 1.116] 0.646 1.043 [0.958; 1.135] 0.329 1.041 [0.893; 1.213] 0.606
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escalation [24]. In contrast, the RTOG 9405 trial did not
discern advantages from dose-escalation [25], albeit with
now-outdated techniques. In summary, our data support
the hypothesis that increased radiation doses improve
patient outcomes; however, the potential benefit of
dose-escalation in EC remains inconclusive due to the
heterogeneity of evidence [26].
Nevertheless, there is little debate that IMRT theoret-
ically allows for safer dose-escalation. Dosimetric investi-
gations have determined that advanced IMRT
techniques provide numerical advantages over 3DCRT,
but without outcome differences [27, 28]. This particu-
larly applies to a reduction of high dose exposure to the
OAR. For example, Münch et al. have demonstrated a
significant reduction of the lung V30Gy with VMAT
(6.6%) compared to 3DCRT (11%) and of the heart
V30Gy (17.7% with VMAT vs. 50.4% with 3DCRT) [27].
In contrast, our study failed to demonstrate any signifi-
cant differences in OAR dose exposure. However,
slightly lower doses to the spinal cord and the heart
were observed for IMRT and MLD was equal despite a
larger PTV volume by trend of IMRT patients. Of note,
the nature of IMRT and arc therapy results in increased
low-dose areas to the heart and lungs, the ramifications
of which are also unclear presently. In the study of
Table 3 Acute toxicities related to radiotherapy in the groups
of 3DCRT and IMRT
3DCRT IMRT p-value
(n = 49) (n = 44)
Dysphagia – no. (%) 0.067
absolute 21 (42.9) 31 (70.5)
G1 4 (8.2) 9 (20.5)
G2 15 (30.6) 15 (34.1)
G3 2 (4.1) 6 (13.6)
G4 0 1 (2.3)
Radiodermatitis – no. (%) 0.638
absolute 14 (28.6) 17 (38.6)
G1 9 (18.3) 13 (29.6)
G2 3 (6.1) 2 (4.6)
G3 2 (4.1) 2 (4.6)
G4 0 0
Nausea/Vomiting – no. (%) 0.602
absolute 11 (22.4) 9 (20.5)
G1 8 (16.3) 4 (9.1)
G2 2 (4.1) 4 (9.1)
G3 1 (2.0) 1 (2.3)
G4 0 0
Mucositis – no. (%) 0.518
absolute 7 (14.3) 7 (15.9)
G1 2 (4.1) 0
G2 4 (8.2) 4 (9.1)
G3 1 (2.0) 3 (6.8)
G4 0 0
Bleeding – no. (%) 0.341
absolute 1 (2.0) 0
G1 1 (2.0) 0
G2 0 0
G3 0 0
G4 0 0
Pneumonitis – no. (%) 0.557
absolute 3 (6.1) 1 (2.3)
G1 1 (2.0) 0
G2 2 (4.1) 1 (2.3)
G3 0 0
G4 0 0
Table 4 Dosimetric parameters related to radiotherapy in the
groups of 3DCRT and IMRT
3DCRT IMRT p-value
(n = 39) (n = 37)
Boost concept – no. (%) <0.001
sequential 36 (92.3) 16 (43.2)
integrated 0 (0) 16 (43.2)
none 3 (7.7) 5 (13.5)
PTV volume - ml 0.060
Mean 667 796
Median 657 755
Range 229-1236 193-1715
Boost PTV volume - ml 0.139
Mean 236 192
Median 230 175
Range 73-528 24-624
Mean lung dose - Gy 0.651
Mean 12.6 12.2
Median 12.3 12.4
Range 4.8-20.2 3.1-18.9
Mean heart dose - Gy 0.158
Mean 18.1 14.2
Median 19.7 14.5
Range 0.4-38.8 0.2-37.5
Spinal cord Dmax - Gy 0.229
Mean 36.8 35.1
Median 38 36.3
Range 14.2-45.9 8–43.2
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Münch et al., the V5Gy of the lungs and the heart were
90.1% and 100% with VMAT compared to 79.7% and
91% with 3DCRT, respectively [27]. Using rotational
techniques, low-dose areas to the lung have been higher
in some studies than the recommended limits in other
(lung cancer) studies [13, 29]. It cannot go unmentioned,
however, that inverse-planned therapies (e.g. IMRT, arc
therapy, etc.) are heavily dependent on nuances of treat-
ment planning, technique, delivery, and optimization,
which can lead to a variety of potential results [30]. The
use of helical IMRT herein has heretofore never been
reported as a modality of IMRT delivery, and could be
of further interest for future investigations.
Though there is a knowledge gap regarding the role of
IMRT in EC, compelling data suggest that IMRT and
other advanced techniques may decrease postoperative
complications when used in the setting of nCRT, thus
potentially decreasing surgical morbidity and mortality
[17]. Notably, Lin et al. analyzed multiple cancer
registries and performed inverse probability of treatment
weighting-adjusted multivariate analysis [31]. Therein,
radiation modality (3DCRT vs. IMRT) was independ-
ently associated with all-cause, other, and cardiac-
specific mortality. It is thus important to be cognizant of
cardiac doses in a neoplasm for which the heart was
historically not a major priority but long-term survival is
now increasing; this is similar to the findings of the
RTOG 0617 trial in locally advanced non-small cell lung
cancer (NSCLC) [32]. Because IMRT affords lower car-
diac doses for both tumors, it has been postulated
that IMRT should be the standard for NSCLC, despite
a similar lack of comparative data in both NSCLC
and EC [33].
There are several limitations of our study. In addition
to the retrospective nature and smaller sample size, it is
recognized that groups were somewhat imbalanced in
terms of tumor location. The rather short follow-up time
may also likely underestimate cardiac events, as these
typically take at least 5–10 years to develop. Although
the year of treatment was not a significant factor on
outcome in UVA, advancements in diagnostics and
treatment options after the first line during the inclusion
period of twelve years may cause an undiscovered bias.
Other newer supportive technologies also cannot be
overlooked, such as staging PET and 4-dimensional CT
planning. Moreover, patients with poor KPS were ex-
cluded, which also contribute a nontrivial proportion of
EC patients. Also, limiting applicability were the low
numbers of adenocarcinoma, as well as institutional/re-
gional biases in referring patients for surgery versus
definitive therapy. Taken together, however, our data
should ideally signal other reports as to whether IMRT
is indeed appropriate for several patient subgroups over
3DCRT.
If clinical benefits of IMRT in the definitive and/or
neoadjuvant treatment of EC are eventually proven, it
could signal further testing of an even more new modal-
ity known as proton beam therapy. Though issues with
economic costs remain, this modality has been also asso-
ciated with low perioperative complications, which could
potentially offset these costs [34–36]. A randomized trial
of photons versus protons for EC is currently underway
(NCT01512589).
Conclusions
These data showed that when comparing 3DCRT and
IMRT, survival of patients with esophageal cancer is not
affected. However, we found a lower rate of local
relapses in the IMRT group potentially owing to dose-
escalation. Further validation is needed from prospective
studies.
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